{"success":true,"limit_reached":false,"status_code":200,"error_message":null,"csv":null,"symbol":"INAB","asset_type":"Common Stock","name":"In8bioÂ Inc","description":"IN8bio, Inc., a clinical-stage biotechnology company, is focused on developing new therapies for the treatment of cancers, including solid tumors using genetically modified, autologous, allogeneic gamma-delta T cells. The company is headquartered in New York, New York.","central_index_key":"1740279","exchange":"NASDAQ","currency":"USD","country":"USA","sector":"LIFE SCIENCES","Industry":"BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)","address":"EMPIRE STATE BUILDING, 350 5TH AVENUE, SUITE 5330, NEW YORK, NY, US","fiscal_year_end":"December","latest_quarter":"2024-09-30","market_capitalization":"23433800","ebitda":"-30632000","pe_ratio":"None","pe_growth_ratio":"None","book_value":"0.576","dividend_per_share":"None","dividend_yield":"None","earnings_per_share":"-0.74","revenue_per_share_ttm":"0","profit_margin":"0","operating_margin_ttm":"0","return_on_assets_ttm":"-0.776","return_on_equity_ttm":"-1.804","revenue_ttm":"0","gross_profit_ttm":"0","diluted_eps_ttm":"-0.74","quarterly_earnings_growth_yoy":"0","quarterly_revenue_growth_yoy":"0","analyst_target_price":"4.75","trailing_pe":"-","forward_pe":"-","price_to_sales_ratio_ttm":"-","price_to_book_ratio":"2.729","ev_to_revenue":"-","ev_to_ebitda":"-1.153","beta":"1.74","fifty_two_week_high":"1.74","fifty_two_week_low":"0.217","fifty_day_moving_average":"0.303","two_hundred_day_moving_average":"0.656","shares_outstanding":"72483000","dividend_date":"None","ex_dividend_date":"None"}